Lantern Pharma actively manages a patent portfolio that includes over 100 issued patents and pending applications across 14 patent families. This approach stand as proof of our constant innovation using A.I. and machine learning to develop cancer treatments, and our focused dedication to the progress of oncology treatments.
General Application
RADR
Patent Appliaion Title
Method and System for Predicting Blood Brain Barrier Permeability (PCT/US24/19851)
Patent Application Summary
Modeling BBB Permeablity
Countries
PCT
Priority Date
2024-03-14
General Application
RADR
Patent Application Title
Computerized systems and methods for ensemble model-based drug discovery (PCT/US2023/064050)
Patent Application Summary
Ensemble-based modeling
Countries
Pending in US, Canada, China, EU, Korea, Australia
Priority Date
2023-03-09
General Application
RADR
Patent Application Title
Machine Learning to Identify Gene Signature Response
Patent Application Summary
Model methodology
Country
Pending in US
Priority Date
2021-03-01
General Application
RADR
Patent Application Title
Identifying Cancer Types or Subtypes Suitable for Treatment with a Drug Candidate
Patent Application Summary
Model to connect subtypes with drug candidates
Countries
Pending in US
Priority Date
2021-05-18
General Application
RADR – Drug Discovery
Patent Application Title
Gene signature of response to agent to identify tumor indications based on machine learning techniques and methods of use thereof
Patent Application Summary
Identifying drug responsiveness using scoring of one or more binary mutations.
Countries
US
Priority Date
2022-02-28
General Application
LP-300
Patent Application Title
Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer (PCT/US20/21615)
Patent Application Summary
NSCLC and Female (non/never smokers)
Countries
Pending in US, Australia, Canada, Brazil, Mexico, Japan, China, India, Singapore, Korea, EU, Hong Kong,
Priority Date
2021-09-08
General Application
LP-300
Patent Title
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds (14/675,607)
Patent Summary
NSCLC
Countries
US
Priority Date
2015-03-31
General Application
LP-300
Patent Application Title
Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer (PCT/US20/21615)
Patent Application Summary
NSCLC
Countries
Pending in Australia, Canada, Mexico, China, Japan, US, EU, Korea, Brazil, Singapore, Hong Kong
Priority Date
2020-03-08
General Application
LP-300
Patent Application Title
method for determining sensitivity to 2,2'-dithio-bis-ethane sulfonate (PCT/US21/12994)
Patent Application Summary
Solid Tumors
Countries
Pending in Australia, Canada, Mexico, China, Japan, US, EU, Korea
Priority Date
2021-01-11
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof
Augmentation of anti-cancer activity
China ZL200780017354
China, Australia
2007-03-16
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589
France, UK, Denmark, and US
2007-03-16
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Chemoprotective methods and compositions
Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.
CA2648945
Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands, Sweden, Switzerland, and UK
2006-12-13
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
A composition containing a Formula (I) compound, administered in a medically sufficient dosage, to enhance survival and/or delay tumor progression in lung cancer patients undergoing treatment with taxane and/or platinum-based drugs.
LP-300
US9320760
Granted in DE, GB, FR, CH, NL, DK, JP, CA, and AU, Pending in EU
2008-03-14
General Application
LP-184
Patent Application Title
Lyophilized illudins and analogs
Patent Application Summary
LP-184/284 lyophilized products
Countries
Pending in Taiwan
Priority Date
2024-09-18
General Application
LP-184
Patent Application Title
Treating liver cancers with hydroxyureamethyl acylfulvene (PCT/US24/43699)
Patent Application Summary
LP-184 and liver cancer
Countries
PCT
Priority Date
2024-08-23
General Application
LP-184
Patent Application Title
Cancer drug sensitivity determining markers (PCT/US21/72496)
Patent Application Summary
Solid Tumors
Countries
Pending in US, China, Mexico, Canada, Japan, Australia, EU, Korea
Priority Date
2021-11-18
General Application
LP-184
Patent Application Title
Method for treating renal cell carcinoma or cancer (PCT/US24/19456)
Patent Application Summary
LP-184 and Renal Cancer
Countries
PCT
Priority Date
2024-03-11
General Application
LP-184
Patent Application Title
Method for treating breast cancers and PARP resistant breast cancers (PCT/US23/70328)
Patent Application Summary
LP-184 and PARP Resistant Breast Cancer
Countries
Pending in US, Japan, Canada, EU
Priority Date
2023-07-17
General Application
LP-184
Patent Application Title
Method for treating tumors with hydroxyureamethyl acylfulvene and radiation (PCT/US2022/080150)
Patent Application Summary
LP-184 and Radiation
Countries
Pending in Australia, Canada, Mexico, Japan
Priority Date
2022-11-18
General Application
LP-184
Patent Application Title
Treating cancers with combinations of PARP inhibitor and acylfulvenes
Patent Application Summary
LP-184 and PARP Inhibitors
Countries
Pending in US, Canada, Mexico, Japan, EU
Priority Date
2022-07-29
General Application
LP-184
Patent Application Title
Methods for treating cancers with spironolactone and acylfulvenes
Patent Application Summary
LP-184 and Spironolactone
Countries
Pending in China, Mexico, Japan, EU, Australia, Korea
Priority Date
2022-07-29
General Application
LP-184
Patent Application Title
Method for Treating Lung Cancer and Non-Small Cell Lung Cancer (PCT/US22/71676)
Patent Application Summary
Lung cancer and NSCLC
Countries
Pending in US, Canada, Mexico, Korea, Japan, China, Australia, EU
Priority Date
2022-04-12
General Application
LP-184
Patent Title
Method for treating rhabdoid tumor
Patent Summary
Rhabdoid Tumor
Countries
Granted in US, EU (Unitiary Patent), Pending in Canada, Japan, and Australia
Priority Date
2021-12-20
General Application
LP-184
Patent Application Title
Treatment of Brain Metastasis Using Illudins or HydroxyUreaMethyl Acylfulvene
Patent Application Summary
Brain Cancer Metastatsis
Countries
Pending in US, Canada, Japan, Mexico, Brazil, China, Korea, Australia, EU
Priority Date
2022-01-10
General Application
LP-184
Patent Application Title
Hydroxyureamethyl-acylfulvene for treating brain cancer or cns cancer (PCT/US202 l/026907)
Patent Application Summary
Brain Cancer and CNS
Countries
Pending in Japan, Canada, China, Brazil, Korea, Australia, EU, Mexico
Priority Date
2021-04-12
General Application
LP-184
Patent Application Title
Method for treating pancreatic cancer (PCT/US2021/031606)
Patent Application Summary
Pancreatic Cancer
Countries
Pending in Japan, Brazil, Canada, Mexico, China, Korea, Australia, EU, US
Priority Date
2021-10-05
General Application
LP-184
Patent Application Title
Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers
Patent Application Summary
Solid Tumors
Countries
Pending in US, Canada, EU, Japan, China, Australia, Hong Kong
Priority Date
2018-10-14
General Application
LP-184
Patent Title
Illudins Analogs (PCT/US19/49555)
Patent Summary
LP-184 Molecule
Countries
Granted in US, India, Japan, Mexico, Pending in China, Korea, Australia, EU, Canada
Priority Date
2021-03-01
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Cancer with Acylfulvene and Radiation
Patent Summary
This is application is directed to methods for treating Cancers by administration of HydroxyUreaMethyl Acylfulvene with radiation doses.
Countries
EU, US
Priority Date
11/18/2022
Irofulven
Illudin analogs useful as anticancer agents
acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment
US7655695
EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)
2010-02-02
Next Generation Illudins
Illudin analogs, used thereof, and methods for synthesizing the same
This application is directed to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof. A new and potentially more potent illudin is disclosed in this application.
PCT/US19/49555
Granted in US, Japan, Mexico, Pending in EU, Canada, India, China, Korea
2019-09-04
General Application
LP-284
Patent Title
Illudins analogs (PCT/US19/49555)
Patent Summary
LP-184 / 284 Molecule
Countries
Granted in US, India, Japan, Mexico, Pending in China, Korea, Australia, EU, Canada
Priority Date
2021-03-01
Next Generation Illudins
Illudin analogs, used thereof, and methods for synthesizing the same
This application is directed to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof. A new and potentially more potent illudin is disclosed in this application.
PCT/US19/49555
Granted in US, Japan, Mexico, Pending in EU, Canada, India, China, Korea
2019-09-04
General Application
LP-284
Patent Application Title
Lyophilized illudins and analogs
Patent Application Summary
LP-184/284 lyophilized products
Countries
Pending in Taiwan
Priority Date
2024-09-18
General Application
LP-284
Patent Application Title
Treating cancers with combinations of acylfulvenes with ibrutinib and/or bortezomib (PCT/US2023/024759)
Patent Application Summary
LP-284 and Ibrutinib/bortezomib
Countries
Pending in US, Japan, Canada, China, Australia, Mexico, EU
Priority Date
2023-06-07
General Application
LP-284
Patent Application Title
Methods for treating cancers with spironolactone and acylfulvenes
Patent Application Summary
LP-284 and Spironolactone
Countries
Pending in China, Mexico, Japan, EU, Australia, Korea
Priority Date
2022-07-29
General Application
Positive HydroxyUreaMethyl Acylfulvene
Patent Application Title
Method For Treating Blood Cancers
Patent Application Summary
LP-284 and Blood Cancers
Countries
Pending in Australia, US
Priority Date
2022-05-03
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
